Cogent Biosciences, Inc. (NASDAQ: COGT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $18.00 price target on the stock.
Cogent Biosciences Reports First Quarter 2024 Financial Results [Yahoo! Finance]
Cogent Biosciences Reports First Quarter 2024 Financial Results
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Cogent Biosciences, Inc. (NASDAQ: COGT)
Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor [Yahoo! Finance]